StreetAlpha.app
Home › Stocks › TLSA

Tiziana Life Sciences Ltd (TLSA)

$0.65
▲ +9.53%
LAST CLOSE · NOV 17

Tiziana Life Sciences develops antibody therapies for neurodegenerative and neuroinflammatory diseases from its base in London. It last closed at $0.65 on Nov 17, up 9.53% on the day. TLSA last reported earnings on Fri, Sep 18, 2026.

AI Auto Pilots
Is TLSA in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2024
Results
Net income
−$11.9M
Free cash flow
−$1.5M
Balance sheet
Cash & equivalents
$3.7M
At Dec 31
Shareholder equity
$3.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: −$26.1M−$26.1MFY2020FY2021: −$23.4M−$23.4MFY2021FY2022: −$15.4M−$15.4MFY2022FY2023: −$17.7M−$17.7MFY2023FY2024: −$11.9M−$11.9MFY2024

From TLSA's SEC filings, latest 20-F for the period ending Dec 31, 2024 (filed May 1). Per share figures are left out because the US listing can represent a different number of shares.

Last report
Sep 18
2026 · Time not announced
Reported EPS
-$0.05
vs $0.00 est.
Year-ago EPS
-$0.05
Same quarter last year
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated TLSA in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 980.2% upside

Based on 1 analyst who set a price target on TLSA in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.65.

Low $7.00Avg $7.00High $7.00
Blue marker: last close $0.65
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
BTIGReiterated
Sep 22Buy$7
BTIGInitiated
Sep 3Buy$7
DateFirmActionRatingPrice target
Sep 22BTIGReiteratedBuy$7
Sep 3BTIGInitiatedBuy$7
Loading…

Technical Analysis

TLSA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 16% below its 20 day and 40% below its 50 day average. It is 78% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38). The nearest support is the swing low (Nov 5) at $0.59, and the nearest resistance the Pivot at $0.66.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 12.5%/day
Key levels
$1.9052 week high+192.3%
$1.16200 day average+78.5%
$0.99100 day average+52.3%
$0.9150 day average+40.0%
$0.7520 day average+15.4%
$0.74Pivot R1+13.8%
$0.70Swing high (Nov 9)+7.7%
$0.66Pivot+1.5%
$0.65Last close
$0.59Swing low (Nov 5)−9.2%
$0.57Pivot S1−12.3%
$0.5552 week low−15.4%
Indicators
RSI (14)38.46Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic11.9Near the bottom of its rangeOversold
ADX (14)33.4Trending down
Williams %R-75.6Oversold below −80, overbought above −20Neutral
CCI (20)-47.9Oversold below −100, overbought above 100Neutral
Rate of change−6.1%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 12.5% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TLSA

What happened before

See how TLSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TLSA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TLSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TLSA in the last 90 days.

Loading…

See today’s whale options flow across the market →

TLSA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲16 buying vs 12 selling
  • ▲Shares held by funds +65.0%
  • ▲Funds holding +4
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding3632+12.5%
In funds' top 1000–
Held by funds–––
New / increased7 / 96 / 8+14.3%
Reduced / sold out9 / 34 / 7+9.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TLSA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TLSA is in one of them and how their past TLSA trades turned out.

TLSA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TLSA in an article yet. Here's the latest on the wider market.

About Tiziana Life Sciences

Tiziana Life Sciences is a biotechnology company based in London, England, that develops treatments for neurodegenerative and neuroinflammatory diseases. Its main candidate, Foralumab, is an antibody being tested as a nasal treatment for conditions such as secondary progressive multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. The company is focused on these clinical programs and aims its work at patients with these conditions.

Headquarters
London, England, United Kingdom